Privé Aesthetics carries both compounded semaglutide and compounded tirzepatide as part of our medically supervised weight-loss program. The right molecule for a given patient is a clinical decision made at consultation, based on medical history, prior response, side-effect tolerability, treatment goals, and cost considerations. This is the honest comparison — how the two molecules differ, what we factor in when prescribing, and what the program looks like in either case.
Compounded GLP-1 therapy has become one of the most discussed topics in our consultation room. Patients often arrive having decided which molecule they want, sometimes based on what they have read, sometimes based on what a friend takes. We treat the decision as more nuanced than that. Both molecules have meaningful clinical roles; the question is which one fits a specific patient at a specific point in their care, and how we structure the program around that choice.
The mechanism difference, briefly
Compounded semaglutide activates the GLP-1 receptor — glucagon-like peptide-1, a naturally occurring incretin hormone that slows gastric emptying, reduces post-meal glucose spikes, and signals appetite-regulation centers in the brain to reduce hunger.
Compounded tirzepatide activates both the GLP-1 receptor and the GIP receptor — glucose-dependent insulinotropic polypeptide, a second incretin signal. The dual activation produces a different appetite and metabolic response than GLP-1 alone, and individual patients may respond differently to single-receptor vs dual-receptor mechanisms.
What this means in practice: neither molecule is universally "better." The dual mechanism of tirzepatide gives it a different clinical profile than semaglutide, but individual physiology and response variability mean some patients do well on one and not the other. The right answer for a specific patient is a consultation conversation.
The honest side-by-side
| Factor | Compounded semaglutide | Compounded tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single receptor) | GLP-1 and GIP dual receptor agonist |
| Cadence | Once weekly self-administered subcutaneous injection | Once weekly self-administered subcutaneous injection |
| Privé pricing | Starting at $350/month; first month includes labs + consultation | Starting at $500/month; first month includes labs + consultation |
| Side-effect profile | Nausea, reduced appetite, gastrointestinal effects; usually transient with titration | Similar profile; nausea, appetite suppression, GI effects; usually transient |
| Contraindications | Medullary thyroid cancer history, MEN2, pancreatitis history, pregnancy, breastfeeding | Same as semaglutide |
| Regulatory status | Compounded preparation; not FDA-approved as a finished drug product | Compounded preparation; not FDA-approved as a finished drug product |
| Pharmacy provenance | U.S. licensed, FDA-registered compounding pharmacy | Same pharmacy |
| Physician oversight | Dr. Gregory Gardner, DO (Medical Director) | Same oversight |
How we decide which one for which patient
The decision is made at consultation, integrating four factors:
One: medical history and contraindications. Both molecules share similar contraindication lists. If a patient has a history of pancreatitis, multiple endocrine neoplasia syndrome type 2, or medullary thyroid cancer (personal or family), neither molecule is appropriate. Pregnancy and breastfeeding are absolute contraindications. Other medical conditions can push the decision one way or another based on individual factors.
Two: prior response. Patients who have previously tried one molecule and either responded or didn't bring useful information into the next decision. We honor what the patient's body has already told us.
Three: side-effect tolerability. Both molecules can cause nausea during titration. Patients who anticipate poor tolerance of GI side effects may benefit from a slower titration on either molecule; patients who have struggled with one before may prefer to try the other.
Four: cost. At $350/month vs $500/month at Privé, the cost difference is real over a 6-12 month program. Patients budget-constrained between the two may reasonably choose semaglutide; patients more focused on the dual-mechanism profile may choose tirzepatide despite the higher cost.
What both programs share
The structural framework is the same regardless of molecule. The full program structure is detailed in the tirzepatide post, but the elements are identical for both:
Month 1: comprehensive consultation, medical history, baseline lab work (CMP, lipid panel, A1C, thyroid, additional tests as indicated by history). Initial prescription titration.
Months 2-4: titration through tolerance. Dose adjustments at monthly check-ins based on response and side-effect profile. Switching molecules during this phase is a possibility if response or tolerability suggests it.
Months 5+: maintenance + monitoring. Continued monthly prescriptions and check-ins. Periodic lab work depending on clinical indication.
Both programs include physician oversight (Dr. Gregory Gardner, DO), compounding through a U.S. licensed, FDA-registered pharmacy, and the option to discontinue at any time.
The compliance framing
We do not make brand-equivalence claims for either compounded molecule. We do not claim FDA approval for either compounded preparation as a finished drug product. We do not promise specific weight loss outcomes for either molecule. Compounded semaglutide and compounded tirzepatide are prescription-only preparations made for the individual patient under physician prescription, in accordance with applicable compounding regulations — we treat them that way in marketing and in clinical practice.
Patients who want branded finished pharmaceutical drugs should pursue that pathway through their primary care physician. Patients who want supervised, monitored access to a compounded peptide preparation under physician prescription are the appropriate candidates for either program at Privé.
How to start
Schedule a consultation. We discuss your medical history, prior weight-loss attempts, current state, lab work needs, and goals. Based on that conversation, we recommend a starting molecule (or sometimes recommend deferring the GLP-1 conversation entirely if it isn't the right intervention). The first-month program fee includes the consultation and baseline labs — you're not committing to a year of treatment before you've had the conversation about whether it's the right treatment.
Frequently asked
What is the difference between compounded semaglutide and compounded tirzepatide?
Both are GLP-1 receptor agonists prescribed for medically supervised weight management. Compounded semaglutide activates the GLP-1 receptor only. Compounded tirzepatide activates both the GLP-1 and GIP receptors, giving it a dual mechanism that may produce different appetite and metabolic responses. The right molecule for a given patient is determined at consultation.
Which one is more effective?
Individual response varies. Some patients respond better to one molecule than the other. We do not make general efficacy claims in marketing because the responsible clinical answer depends on the patient's medical history, prior response, and treatment goals. The decision is made at consultation, sometimes after a trial of one or the other.
How do the prices compare at Privé?
At Privé Aesthetics in Dallas, compounded semaglutide programs start at $350/month and compounded tirzepatide programs start at $500/month. Both fees include the first-month consultation and baseline lab work. Final pricing depends on dose titration and program duration.
Can I switch between semaglutide and tirzepatide?
Yes. Patients sometimes start on one molecule and switch based on response, side-effect tolerance, or cost considerations. The switch is a clinical decision made at a check-in with the supervising provider; we do not make this change automatically.
Are the side effects different?
Both molecules share a similar side-effect profile — nausea (particularly during titration), reduced appetite, gastrointestinal effects. Individual tolerability varies between the two. The titration cadence and monthly check-ins help us identify and address side effects early.
Are both molecules compounded at the same pharmacy?
Yes. Both compounded semaglutide and compounded tirzepatide preparations at Privé are sourced through a U.S. licensed, FDA-registered compounding pharmacy under physician prescription. We do not claim FDA approval for either compounded preparation as a finished drug product.